Every Software as a Medical Device eventually has to answer one question: does it actually work, safely, for the people and the purpose it was built for? SaMD clinical evaluation is how that question gets answered with evidence rather than assertion. It is one of the most misunderstood parts of bringing medical software to market, often confused with running a clinical trial or with testing that the software functions correctly, when it is neither of those things exactly.
This page explains what SaMD clinical evaluation is, how it differs from the activities teams tend to confuse it with, what evidence it draws on, and how it supports a regulatory submission. For the wider context, see our complete guide to Software as a Medical Device.
What Is SaMD Clinical Evaluation?
SaMD clinical evaluation is the process of generating and assessing clinical evidence to demonstrate that a Software as a Medical Device is safe and effective for its intended use. It is the structured argument, backed by data, that the software does what it claims to do for the patients and the clinical purpose it targets.
The emphasis on intended use is deliberate. A SaMD is not evaluated in the abstract; it is evaluated against the specific claim its maker makes about it. A tool that flags a possible arrhythmia for a clinician to review is held to a different evidentiary standard than one that autonomously diagnoses a condition, because the claims and the risks differ. Clinical evaluation is where that claim meets evidence, and where a regulator decides whether the two match.
It is also not a single event. Clinical evaluation begins during development, culminates in the evidence submitted for market authorization, and continues after launch as real-world data accumulates and the software evolves. Treating it as a box to tick just before submission is one of the most common and expensive mistakes a team can make, because the evidence a strong evaluation needs is often generated over months or years, not assembled in a final sprint.
Clinical Evaluation vs. Software Validation vs. Clinical Trials
SaMD clinical evaluation is often confused with two related but distinct activities, and keeping them separate is essential to understanding what each requires. Software validation, clinical trials, and clinical evaluation answer different questions and sit at different points in the development of a medical software product.
Activity | The question it answers | What it is |
Software validation | Does the software work as designed and specified? | An engineering activity that confirms the software correctly implements its requirements |
Clinical trial | What happens when the software is used with real patients? | A structured study that can generate clinical data; one possible source of evidence |
Clinical evaluation | Is the software safe and effective for its intended use? | The overall assessment of all clinical evidence against the intended purpose |
The distinction matters in practice. Software validation proves the code does what the specification says; it is necessary, but a perfectly validated piece of software can still fail to be clinically useful. A clinical trial is one way to gather clinical data, but not every SaMD requires one, and a trial on its own is not an evaluation. Clinical evaluation is the broader assessment that draws on evidence from validation, from trials in which they are used, from published literature, and from real-world data, and weighs all of it against the intended use. Understanding which activity a given requirement belongs to keeps a team from over-investing in one while neglecting another.
What Goes Into a SaMD Clinical Evaluation
SaMD clinical evaluation draws on several sources of clinical evidence, assembled to build a complete picture of safety and effectiveness. No single source is required in every case; the mix depends on the software, its risk, and the claims being made. Common sources include data from clinical investigations, peer-reviewed published literature, and real-world or performance data gathered from actual use.
The International Medical Device Regulators Forum (IMDRF) provides the framework most widely used framework for structuring a SaMD clinical evaluation. It rests on three components, and a strong evaluation addresses all three:
- Valid clinical association: Is there a valid, established link between the software’s output and the clinical condition it targets? This asks whether the thing being measured genuinely relates to the clinical state the SaMD claims to address.
- Analytical validation: does the software correctly and reliably process its input to produce the intended output? This confirms the SaMD computes what it claims, accurately and consistently.
- Clinical validation: does the output achieve the intended purpose in the target population, in real clinical use? This asks whether the software actually delivers the clinical benefit it promises for the people it is meant to serve.
The depth of evidence required scales with the software’s risk. A higher-risk SaMD, one that informs or drives decisions about a serious or critical condition, demands stronger evidence across all three components than a lower-risk tool. This is why the SaMD’s risk classification shapes the clinical evaluation from the start.
The evidence is then compiled and documented, typically into a clinical evaluation report or an equivalent record, that becomes part of the regulatory submission. That report is not a formality; it is the reasoned, data-supported case that a regulator reviews to decide whether the software is safe and effective for what it claims to do.
How Clinical Evaluation Fits the Regulatory Pathway and Quality System
SaMD clinical evaluation feeds directly into the regulatory pathway. The evidence it produces is a core part of what a regulator examines when deciding whether to clear, grant, or approve the software. Whichever regulatory pathway a SaMD follows, the clinical evaluation supplies the safety and effectiveness case that pathway depends on, scaled to the product’s risk.
Clinical evaluation does not sit beside the rest of the development process; it lives within it. It draws on the risk management activity carried out under ISO 14971, and it is documented within the quality management system that governs the whole lifecycle. Evidence, risk, and quality are threads of the same fabric, and a clinical evaluation built in isolation from them tends to unravel under review.
After launch, clinical evaluation continues. Real-world performance data feeds post-market surveillance, and any significant change to the software may require the evidence to be revisited. This is especially true for AI-enabled medical devices, where a model that changes over time raises ongoing questions about whether the original evidence still holds. Planning for that continuity from the beginning is far cheaper than reconstructing it later.
Sequenex supports sponsors by engineering the software and the data and evidence infrastructure that clinical evaluation depends on, built under an ISO 13485-certified quality management system so that the records supporting the evaluation are produced by the process rather than assembled after the fact. The clinical strategy, the intended use, and the regulatory submission remain the sponsor’s, while the technical foundation for generating and documenting evidence is built to support them.
Frequently Asked Questions
What is SaMD clinical evaluation?
SaMD clinical evaluation is the process of generating and assessing clinical evidence to show that a Software as a Medical Device is safe and effective for its intended use. It weighs evidence from sources such as clinical investigations, literature, and real-world data against the software’s specific claims.
Is clinical evaluation the same as software validation?
No. Software validation confirms that the software works as designed and meets its specifications, which is an engineering activity. Clinical evaluation is broader, assessing whether the software is clinically safe and effective for its intended use. A SaMD can be fully validated and still require clinical evaluation to demonstrate clinical benefit.
Does every SaMD need a clinical trial?
Not necessarily. A clinical trial is one way to generate clinical evidence, but some SaMD rely on published literature, existing data, or real-world performance data instead. Whether a trial is needed depends on the software’s risk, its claims, and the strength of other available evidence.
What are the three components of SaMD clinical evaluation?
Under the IMDRF framework, the three components are valid clinical association (the output genuinely relates to the clinical condition), analytical validation (the software correctly and reliably produces its output), and clinical validation (the output achieves the intended purpose in the target population).
When does clinical evaluation happen?
Clinical evaluation begins during development, is central to the evidence submitted for market authorization, and continues after launch through post-market surveillance. It is an ongoing process rather than a one-time step, particularly for software that changes over time.
Clinical evaluation is where a Software as a Medical Device earns the trust of clinicians, patients, and regulators, and it is far easier when the software and its evidence infrastructure are built for it from the start. Sequenex builds SaMD under an ISO 13485-certified quality management system, engineering the data pipelines, documentation, and software foundation that clinical evaluation depends on, while your team leads the clinical strategy and owns the submission. Explore our medical device software development services to see how we support the journey to market.
